PetNet inks radiopharma deal with Lantheus

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

Radiopharmaceutical provider PetNet Solutions, a wholly owned subsidiary of Siemens Medical Solutions, has executed a supply agreement with Lantheus Medical Imaging, a contrast agent and biomarker developer, to provide BMS747158 for PET imaging of cardiac perfusion as part of a Phase II and Phase III trial.

PetNet and Siemens have previously supplied all of the clinical trial doses for the Lantheus phase I study, the company said. BMS747158 is Lantheus' novel fluorine 18-labeled PET tracer for myocardial perfusion imaging in subjects under rest and stress conditions.

The Toronto-based PetNet operates a network with 52 radiopharmacies and distribution centers that manufacture and distribute PET biomarkers to hospitals, clinics and research facilities.